RIVAROXABAN (Xarelto) prior authorization at Centene
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Centene requires Factor Xa Inhibitor prior-authorization documentation for RIVAROXABAN (Xarelto): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Centene reviews RIVAROXABAN (Xarelto) prior authorizations against its medical policy for Factor Xa Inhibitor. Centene-specific context: Largest Medicaid MCO in US. Markets under Ambetter (ACA), Wellcare (MA), and state-specific Medicaid brands. State-specific appeal processes vary; check state Medicaid handbook.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Factor Xa Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Centene's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Marketplace network adequacy issues
- Medicaid step therapy
- Specialty drug exclusions
RIVAROXABAN (Xarelto)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring warfarin first
- Non-formulary
Brand: Xarelto.
Manufacturer patient-assistance program: Xarelto Cares — relevant when a Centene denial sticks and the patient needs bridge access while appealing.
How Centene approaches Direct oral anticoagulants (DOACs) PAs
For RIVAROXABAN (XARELTO), check whether the current Centene Direct oral anticoagulants (DOACs) policy cites medicaid step therapy. Pharmacy-benefit review for RIVAROXABAN (XARELTO) at Centene is routed through Envolve Pharmacy Solutions / state-specific Medicaid PBMs. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Centene; if denied, use the filing date and route printed on that denial notice. Centene's warfarin-step-first policy is defensible only when the patient lacks documented intolerance, labile INR, drug-interaction risk, or non-valvular AF with stroke risk — citing AHA/ACC/HRS 2023 typically overturns. Centene is domiciled in MO, so unresolved appeals escalate to the MO insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://ambetterhealth.com/provider-resources) with the same packet plus an applicable, current clinical source supporting RIVAROXABAN (Xarelto)for the patient's indication.
Medicare Advantage cases may have plan reconsideration and independent-review steps. Confirm the current level, forwarding rule, and any expedited pathway directly in the notice before selecting an escalation route.
Centene Medicare Advantage organization determinations operate under 42 CFR Part 422 Subpart D. For RIVAROXABAN (XARELTO), the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. The applicable decision period and any Independent Review Entity routing depend on the request type, current rule, and plan notice. Record the cited source and version, then verify the operational due date against the current notice and CMS materials before relying on it.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Centene denial on DenialHelp.
Contact Centene
- Provider portal: https://ambetterhealth.com/provider-resources
Frequently asked questions
What documentation does Centene need for RIVAROXABAN (Xarelto) prior auth?
Centene's typical PA packet for RIVAROXABAN (Xarelto): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Factor Xa Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Centene?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for RIVAROXABAN (Xarelto) at Centene?
Preparation scenarios to check against the current notice and policy include: Marketplace network adequacy issues; Medicaid step therapy; Specialty drug exclusions. These are not measured frequency claims. For RIVAROXABAN (Xarelto), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Will Centene accept a contraindication to warfarin instead of a warfarin trial for RIVAROXABAN (XARELTO)?
Yes — Centene accepts documented warfarin contraindication or intolerance in place of a warfarin trial. Acceptable contraindications include labile INR (TTR <60% on prior warfarin), high bleeding risk (HAS-BLED ≥3), drug-interaction burden, valvular AF (which actually mandates warfarin, not contraindicates), or patient inability to comply with INR monitoring. Cite AHA/ACC/HRS 2023 AF Guideline language for the DOAC-first rationale in non-valvular AF. Pharmacy-benefit handling is routed through Envolve Pharmacy Solutions / state-specific Medicaid PBMs. External-review escalation for Centene fully-insured policies sits with the MO insurance department.
How do I prep for a peer-to-peer with Centene on RIVAROXABAN (Xarelto)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the RIVAROXABAN (Xarelto) PA packet
Open ApprovalHelp — generate a RIVAROXABAN (Xarelto) prior-auth packet tailored to Centene's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com